Health Care & Life Sciences » Biotechnology | Anterogen Co. Ltd.

Anterogen Co. Ltd. | Balance Sheet

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Cash & Short Term Investments
9,985
8,565
12,293
23,111
34,377
Total Accounts Receivable
663
1,036
1,164
1,749
2,697
Inventories
342
507
321
421
554
Other Current Assets
80
99
163
74
95
Total Current Assets
11,070
10,206
13,941
25,355
37,723
Net Property, Plant & Equipment
2,079
2,108
2,169
6,959
7,301
Total Investments and Advances
11
40
42
58
11,322
Intangible Assets
1,649
2,112
2,336
3,026
3,884
Other Assets
-
-
-
30
69
Total Assets
14,809
14,466
18,488
35,428
60,298
ST Debt & Current Portion LT Debt
-
-
-
-
5,127
Accounts Payable
-
273
13
152
535
Other Current Liabilities
356
781
1,319
467
814
Total Current Liabilities
356
1,054
1,332
619
6,476
Long-Term Debt
-
-
-
-
4,195
Provision for Risks & Charges
335
451
516
785
859
Total Liabilities
691
1,505
1,848
1,404
11,530
Common Equity (Total)
14,118
12,961
16,639
34,024
48,768
Total Shareholders' Equity
14,118
12,961
16,639
34,024
48,768
Total Equity
14,118
12,961
16,639
34,024
48,768
Liabilities & Shareholders' Equity
14,809
14,466
18,488
35,428
60,298

About Anterogen Co.

View Profile
Address
Unit 405, Namsung Plaza
Seoul SL 08589
Korea, Republic Of
Employees -
Website http://www.anterogen.com
Updated 09/14/2018
Anterogen Co., Ltd. develops stem cell therapy treatments. Its products include Cupistem and Remodullin injection, Queencell and stem cell conditioned media. In addition, It also offers stem cell banking and analysis services.